# Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life

> **NCT06759077** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Al-Azhar University** · enrollment: 126 (actual)

## Conditions studied

- Kidney Diseases

## Interventions

- **DRUG:** Dapagliflozin (DAPA)

## Key facts

- **NCT ID:** NCT06759077
- **Lead sponsor:** Al-Azhar University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-28
- **Primary completion:** 2024-12-28
- **Final completion:** 2025-12-28
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06759077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06759077, "Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06759077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*